Preparing the AstraZeneca COVID-19 Vaccine at PCN designated sites and end user locations

David Erskine, Director, London Medicines Information Services, Specialist Pharmacy ServicePublished Last updated See all updates

Standard Operating Procedure for preparation of AstraZeneca COVID-19 Vaccine in PCN designated sites and end user locations prior to immediate administration.

Information

A standard operating procedure is attached to this page.

You should also familiarise yourself with our background guide Facilitating pharmaceutical support to PCN designated sites for COVID-19 vaccinations before using this SOP.

 

What to do if you still have questions

If you still have questions you can get in touch with us. However, please first read our service remit; and if you still think we can help, use the email address below.

We're supporting healthcare professionals in England with pharmaceutical aspects of the COVID-19 vaccination programme; read our service remit to find out more.
If you're a healthcare professional in England, get in touch with us if you still have questions

Change history

  1. Updated AVH 3.1 V1.5 to V1.6 to include AZ specific images of vaccine vial and syringe.

  2. Updated to clarify wording on disposal of vaccine and vaccine packaging to prevent theft and misuse

  3. Amended AVH 3.1 to align with AVH 3 in terms of wording about sterile alcohol wipes

  4. Amended AVH 3.2 to restore missing step in process

  5. Updated AVH 3.1 to align with AVH 3 in terms of wording about removal of vaccine vials from refrigerator

  6. Clarification of wording about removal of vaccine vials from refrigerator

  7. Amended needle gauge options for morbidly obese patients in accordance with PHE Guidance.

  8. Avoidance of pooling of vaccine overage added

  9. Clarification on working under the national PGD and inclusion of extra consumables for additional doses incorporated into main text.

  10. Published